Introduction {#Sec1}
============

Tuberculosis (TB) remains one of the health problems in the developing world even after the development of effective treatment \[[@CR1]\]. TB becomes the leading cause of death from a single infectious disease \[[@CR2]\]. Globally, 10.4 million new TB cases were recorded in 2015 \[[@CR2]\], Africa accounting for 26% of the global TB \[[@CR2]\].

Out of the 30 high TB burden countries, Ethiopia ranks 11th \[[@CR2]\] and the prevalence of TB per 100,000 populations in Ethiopia was 482 in 1994 \[[@CR3]\] and declined progressively to 200 in 2014 \[[@CR4]\]. The estimate of TB incidence per 100,000 populations was 431 in 1997 which was declined to 192 in 2015 \[[@CR2]\]. The prevalence of multidrug-resistant (MDR)-TB in Ethiopia has been increasing from 1.6 to 2.3% in new cases and 11.8--17.8% in previously treated TB cases from 2005 to 2014 \[[@CR5]\]. In addition, 17.6% of all TB patients in Ethiopia were co-infected with HIV \[[@CR5]\].

The Federal Ministry of Health of Ethiopia (FMOH) has been implementing a number of strategies specific to TB, TB/HIV, and MDR-TB. Direct Observed Treatment Short-course (DOTS) was recommended by WHO since the mid-1990s. DOTS has been started in Ethiopia in 1992 as a pilot \[[@CR6], [@CR7]\] and since then Ethiopia has been implementing DOTS.

So far, TB treatment outcomes in Ethiopia were evaluated in a limited number of easily accessible health facilities \[[@CR8]--[@CR25]\]. However, treatment outcomes are dependent on adherence to the treatment protocol which is also dependent on the knowledge and commitment of patients and health professionals \[[@CR26]\]. This implies that patients who live in less accessible and geographically distant places could have low level of knowledge that may contribute to the reduced adherence to treatment \[[@CR27], [@CR28]\].

Studies indicated that treatment success rate (TSR) in Ethiopia varies from 26% \[[@CR11]\] to 94.4% \[[@CR13]\] depending on different factors. Therefore, evaluating the treatment outcomes of specific localities such as that of the South Omo Zone (SOZ) could play an important role in addressing the TB control problems of the Zone. The objective of this study was, therefore, to evaluate the TB treatment outcomes and identify associated risk factors in the Jinka General Hospital (JGH), southern Ethiopia.

Main text {#Sec2}
=========

Materials and methods {#Sec3}
---------------------

### Study settings {#Sec4}

The study was carried out using data extracted from medical records of TB patients registered in the JGH between July 2004 and June 2014. The JGH is located in SOZ, southern Ethiopia. According to the 2007 census, the total population of the SOZ was 577,673 (7.5% urban and 92.5% rural) of whom 50% were men \[[@CR29]\]. In the SOZ, the first health center was established in April 1962 (Hospital archive). Presently, the JGH, the only Hospital in the SOZ, has been serving the community since April 2001.

Direct Observed Treatment Short-course was introduced in the Southern Nations and Nationalities People Region (SNNPR), in 1996 \[[@CR30]\] and started in the SOZ in 2001 at the JGH setting (personal communication). Its effectiveness has never been evaluated. The JGH uses first-line TB drugs in a combination of two or more drugs which includes streptomycin (S), ethambutol (E), isoniazid (H), rifampicin (R) and pyrazinamide (Z). Treatment regimens were: short course chemotherapy (SCC)---2(RHZ) plus or minus E or S/followed by 6(EH) or 4(RH) for new patients; 2S(RHZE), 1(RHZE) and 5(RHE) for re-treatment patients, and Long course chemotherapy (LCC)---2S(HE)/10(RE) for patients with serious liver disease \[[@CR31]\]. Since 2009, the continuation phase regimen has been changed from 6(EH) to 4(RH) \[[@CR32]\].

### Definitions {#Sec5}

Tuberculosis patients clinically and, before and after TB treatment were categorized based on guidelines of Ethiopian TB, TB/HIV and leprosy control program and WHO \[[@CR33], [@CR34]\].

### Data collection {#Sec6}

Tuberculosis treatment registers in JGH from July 2004 to June 2014 were used as the data source. The data collected included year of treatment, sex, age, treatment history, type of TB, HIV test result and treatment outcomes. The collected data were entered into an Excel spreadsheet and the data were cross-checked for the correctness before analysis.

### Data analysis {#Sec7}

Data analysis was made by transforming the data from Excel into IBM SPSS Statistics 20. The results were presented using descriptive statistics. The associations between TB treatment outcomes and independent variables were computed using binary logistic regression. Crude odds ratio (COR) and adjusted odds ratio (AOR) were used to present the results. value less than 0.05 was considered statistically significant.

Results {#Sec8}
-------

### Demographic and clinical characteristics of TB patients {#Sec9}

Demographic and clinical characteristics of TB patients were summarized in Table [1](#Tab1){ref-type="table"}. A total of 2156 TB patients (59.4% male) with the age range of 0.25--95 years were registered during the 10 years. The mean, standard deviation and median age of the TB patients were 30.1, 15.4 and 29, respectively. The highest percentage (77.7%) of the cases was in the age range 15--54 years. The proportion of smear-negative pulmonary TB (PTB−) cases, new cases, re-treatment cases and transfer-in cases were 48.4, 92.3, 5.3 and 2.3% respectively. TB/HIV co-infection was 19.6% (315/1604) and higher percentage was recorded in smear-negative PTB (PTB−) patients.Table 1Demographic characteristics of TB patients registered at JGH (July 2004--June 2014)CharacteristicsNumber (%) stratified by type of TBTotal N (%) PTB−PTB+EPTBSex Female420 (40.2)225 (40.7)231 (41.3)876 (40.6) Male624 (59.8)328 (59.3)328 (58.7)1280 (59.4)Age in years \< 15150 (14.4)31 (5.6)119 (21.3)300 (13.9) 15--24137 (13.1)149 (26.9)132 (23.6)418 (19.4) 25--34297 (28.4)202 (36.5)163 (29.2)662 (30.7) 35--44219 (21.0)88 (15.9)80 (14.3)387 (17.9) 45--54116 (11.1)60 (10.8)32 (5.7)208 (9.6) ≥ 55125 (12.0)23 (4.2)33 (5.9)181 (8.4)TB patients category New TB cases976 (93.5)495 (89.5)520 (93.0)1991 (92.3) Re-treatment TB cases53 (5.1)37 (6.7)25 (4.5)115 (5.3) Transfer-in TB cases15 (1.4)21 (3.8)14 (2.5)50 (2.3)HIV test result Non reactive602 (57.7)331 (59.9)356 (63.7)1289 (59.8) Reactive209 (20.0)69 (12.5)37 (6.6)315 (14.6) Unknown233 (22.3)153 (27.7)166 (29.7)552 (25.6)Year of registration for TB treatment July 2004--June 200525 (2.4)48 (8.7)30 (5.4)103 (4.8) July 2005--June 200657 (5.5)27 (4.9)53 (9.5)137 (6.4) July 2006--June 200782 (7.9)39 (7.1)56 (10.0)177 (8.2) July 2007--June 2008104 (10.0)47 (8.5)50 (8.9)201 (9.3) July 2008--June 2009102 (9.8)46 (8.3)31 (5.5)179 (8.3) July 2009--June 2010124 (11.9)43 (7.8)31 (5.5)198 (9.2) July 2010--June 2011189 (18.1)41 (7.4)70 (12.5)300 (13.9) July 2011--June 2012224 (21.5)92 (16.6)87 (15.6)403 (18.7) July 2012--June 201361 (5.8)71 (12.8)72 (12.9)204 (9.5) July 2013--June 201476 (7.3)99 (17.9)79 (14.1)254 (11.8)Total1044 (48.4)553 (25.6)559 (25.9)2156 (100)

### Treatment outcomes {#Sec10}

Treatment outcomes of the cases are summarized in Table [2](#Tab2){ref-type="table"}. Out of 2156 TB patients registered at the JGH between 2004 and 2014, 45.6% (984/2156) was transferred out. Treatment outcomes were available only for 54.4% (1172/2156) of the patients. Out of the later, 13.1, 60.9, 10.2 and 9.1% were cured, treatment completed, died and loss to follow-up, respectively. TSR was 91.5% (43/47), 80.8% (227/281), 78.9% (422/535) and 84.1% (53/63) in transfer-in, smear-positive pulmonary TB (PTB+), HIV negative, and July 2012--June 2013 registered cases respectively. The cure rates were 54.8% (154/281) and 67.8% (154/227) in all cases and PTB+ cases, respectively. Higher numbers of unsuccessful treatment outcomes were recorded in PTB− cases. The TSR showed an increasing trend in the first 5 years and then a declining trend except during 1 year (July 2012 and June 2013).Table 2Treatment outcomes of TB patients in JGH (July 2004--June 2014)CharacteristicsNumber (%) stratified by the treatment outcomesTotal\
N (%) P valueSuccessful treatment outcomes 868 (74)Unsuccessful treatment outcomes 304 (24)CuredTreatment completedDiedT. failure^a^Loss to follow-upInterrupterSex Female66 (14.2)299 (64.3)40 (8.6)0 (0.0)30 (6.5)30 (6.5)465 (39.7)0.059 Male88 (12.4)415 (58.7)79 (11.2)1 (0.1)77 (10.9)47 (6.6)707 (60.3)Age in years \< 155 (3.4)101 (69.7)10 (6.9)0 (0.0)8 (5.5)21 (14.5)145 (12.4)\< 0.001 15--2455 (21.7)145 (57.1)19 (7.5)0 (0.0)22 (8.7)13 (5.1)254 (21.7) 25--3456 (15.3)216 (59.2)39 (10.7)1 (0.3)34 (9.3)19 (5.2)365 (31.1) 35--4423 (10.6)138 (63.3)24 (11.0)0 (0.0)22 (10.1)11 (5.0)218 (18.6) 45--5410 (10.4)50 (52.1)16 (16.7)0 (0.0)12 (12.5)8 (8.3)96 (8.2) ≥ 555 (5.3)64 (68.1)11 (11.7)0 (0.0)9 (9.6)5 (5.3)94 (8.0)TB patients category New TB cases125 (12.0)633 (61.0)107 (10.3)0 (0.0)98 (9.4)75 (7.2)1038 (88.6)\< 0.001 Re-treatment TB cases16 (30.2)22 (51.2)5 (11.6)0 (0.0)3 (7.0)0 (0.0)43 (3.7) Transfer-in TB cases13 (27.7)30 (63.8)1 (2.1)0 (0.0)2 (4.3)1 (2.1)47 (4.0)Type of TB PTB−NA436 (71.5)72 (11.8)NA51 (8.4)51 (8.4)610 (52.0)\< 0.001 PTB+154 (54.8)73 (26.0)24 (8.5)1 (0.4)22 (7.8)7 (2.5)281 (24.0) EPTBNA205 (73.0)23 (8.2)NA34 (12.1)19 (6.8)281 (24.0)HIV test result Non reactive81 (15.1)341 (63.7)29 (5.4)0 (0.0)39 (7.3)45 (8.4)535 (45.6)\< 0.001 Reactive28 (11.9)138 (58.7)41 (17.4)0 (0.0)15 (6.4)13 (5ρ.5)235 (20.1) Unknown45 (11.2)235 (58.5)49 (12.2)1 (0.2)53 (13.2)19 (4.7)402 (34.3)Year of TB treatment July 2004--June 200510 (12.2)43 (52.4)14 (17.1)1 (1.2)13 (15.9)1 (1.2)82 (7.0)\< 0.001 July 2005--June 20069 (8.3)63 (57.8)21 (19.3)0 (0.0)15 (13.8)1 (0.9)109 (9.3) July 2006--June 200713 (8.9)91 (62.3)11 (7.5)0 (0.0)21 (14.40)10 (6.8)146 (12.5) July 2007--June 200818 (11.8)101 (66.0)19 (12.4)0 (0.0)10 (6.5)5 (3.3)153 (13.1) July 2008--June 200920 (16.3)83 (67.5)11 (8.9)0 (0.0)4 (3.3)5 (4.1)123 (10.5) July 2009--June 201019 (13.7)92 (66.2)12 (8.6)0 (0.0)12 (8.6)4 (2.9)139 (11.9) July 2010--June 201121 (11.7)120 (67.0)8 (4.5)0 (0.0)8 (4.5)22 (12.3)179 (15.3) July 2011--June 201215 (14.3)57 (54.3)6 (5.7)0 (0.0)8 (7.6)19 (18.1)105 (9.0) July 2012--June 201319 (30.2)34 (54.0)6 (9.5)0 (0.0)1 (1.6)3 (4.8)63 (5.4) July 2013--June 201410 (13.7)30 (41.1)11 (15.1)0 (0.0)15 (20.5)7 (9.6)73 (6.2)Total154 (13.1)714 (60.9)119 (10.2)1 (0.1)107 (9.1)77 (6.6)1172 (100)*NA* not applicable, *T. failure* ^a^ treatment failure

### Treatment success and associated factors of TB patients {#Sec11}

Multiple logistic regression analysis indicated that male (AOR = 0.70, 95% CI 0.52--0.93) and TB/HIV co-infection (AOR = 0.67, 95% CI 0.46--0.98) were significantly associated with reduced odds of treatment success (Table [3](#Tab3){ref-type="table"}). While patients who transferred-in (AOR = 3.80, 95% CI 1.32--10.94) and PTB+ (AOR = 1.81, 95% CI 1.24--2.64) were significantly associated with the odds of having better treatment success.Table 3Factors associated with treatment success rate TB cases at JGH (July 2004--June 2014)CharacteristicsTotal\
N (%)Treatment success N (%)Crude OR (95% CI)Adjusted OR (95% CI)P valueSex Female465 (39.7)365 (78.5)1.001.00 Male707 (60.3)503 (71.1)*0.68 (0.51--0.89)0.70 (0.52--0.93)0.013*Age in years \< 15145 (12.4)106 (73.1)1.001.00 15--24254 (21.7)200 (78.7)1.36 (0.85--2.19)1.30 (0.79--2.14)0.301 25--34365 (31.1)272 (74.5)1.08 (0.70--1.66)1.18 (0.74--1.87)0.493 35--44218 (18.6)161 (73.9)1.04 (0.65--1.67)1.13 (0.68--1.86)0.645 45--5496 (8.2)60 (62.5)0.61 (0.35--1.07)0.63 (0.35--1.13)0.122 ≥ 5594 (8.0)69 (73.4)1.02 (0.57--1.83)1.04 (0.56--1.91)0.912TB patients category New TB cases1038 (88.6)758 (73.0)1.001.00 Re-treatment TB cases87 (7.4)67 (77.0)1.24 (0.74--2.08)0.94 (0.55--1.62)0.831 Transfer-in TB cases47 (4.0)43 (91.5)*3.97 (1.41--11.16)3.79 (1.31--10.92)0.014*Type of TB PTB−610 (52.0)436 (71.5)1.001.00 PTB+281 (24.0)227 (80.8)*1.68 (1.19--2.37)1.81 (1.24--2.64)0.002* EPTB281 (24.0)205 (73.0)1.08 (0.78--1.48)1.19 (0.84--1.68)0.328HIV test result Non reactive535 (45.6)422 (78.9)1.001.00 Reactive235 (20.1)166 (70.6)*0.64 (0.45--0.91)0.67 (0.45--0.98)0.036* Unknown402 (34.3)280 (69.7)*0.62 (0.46--0.83)*0.81 (0.44--1.49)0.492Year of registration for TB treatment July 2004--June 200582 (7.0)53 (64.6)1.001.00 July 2005--June 2006109 (9.3)72 (66.1)1.07 (0.58--1.94)1.17 (0.63--2.18)0.614 July 2006--June 2007146 (12.5)104 (71.2)1.36 (0.76--2.41)1.62 (0.89--2.93)0.114 July 2007--June 2008153 (13.1)119 (77.8)*1.92 (1.06--3.46)2.29 (1.03--5.09)0.043* July 2008--June 2009123 (10.5)103 (83.7)*2.82 (1.46--5.45)3.29 (1.38--7.84)0.007* July 2009--June 2010139 (11.9)111 (79.9)*2.17 (1.17--4.01)2.53 (1.11--5.75)0.027* July 2010--June 2011179 (15.3)141 (78.8)*2.03 (1.14--3.62)2.37 (1.03--5.45)0.042* July 2011--June 2012105 (9.0)72 (68.6)1.19 (0.65--2.20)1.36 (0.59--3.14)0.474 July 2012--June 201363 (5.4)53 (84.1)*2.90 (1.29--6.54)2.78 (1.01--7.66)0.048* July 2013--June 201473 (6.2)40 (54.8)0.66 (0.35--1.27)0.65 (0.26--1.60)0.348Italic values to show significance

Discussion {#Sec12}
----------

In the present study, the records of TB cases registered at JGH between 2004 and 2014 were extracted and analyzed for the evaluation of the treatment outcomes. The analysis was done for 54.4% (1172/2156) of TB cases. The ratio of male to female cases was 1.5:1, which is in agreement with the reports of WHO \[[@CR2]\] and with those of the previous studies in Ethiopia \[[@CR11], [@CR14], [@CR16], [@CR23], [@CR24]\] and in other countries \[[@CR35]--[@CR39]\]. The larger number of TB cases in males than females could be due to biological differences, the difference in societal roles and access to health facilities \[[@CR40], [@CR41]\].

The finding of this study showed that the percentage of TB was highest in the productive age group (15--54) and it was in agreement with the results of studies conducted in Ethiopia \[[@CR8], [@CR14], [@CR25]\] and Bhutan \[[@CR42]\]. Such findings could be due to the greater mobility of this age group for economic and social reasons.

TB/HIV co-infection recorded in the present study was higher than the average percentages of Ethiopia and that of the Southern region of Ethiopia \[[@CR5]\]. Moreover, it was higher than those of other studies in Ethiopia \[[@CR9], [@CR10], [@CR13], [@CR18], [@CR23]\] and in Spain \[[@CR37]\]. On the other hand, other studies \[[@CR8], [@CR11]\] reported higher percentages of TB/HIV co-infection compared to that of the present study. As suggested by an earlier study, the variation in the percentage of TB/HIV co-infection is mainly attributed to the prevalence of HIV in the study population \[[@CR43]\]. In this study, PTB− cases had higher number of TB/HIV co-infection than PTB+ cases. This is the fact that TB cases with HIV are less likely to be smear-positive \[[@CR44]\].

The TSR recorded, 74%, by this study was less than the target to be achieved, 87%, by 2015 \[[@CR45]\]. It was also less than the TSR reported from the other regions of Ethiopia \[[@CR9], [@CR10], [@CR13], [@CR15], [@CR21], [@CR24]\]. On the other hand, it was similar with that of one study \[[@CR11]\] and greater than that of reporting from the northern Ethiopia \[[@CR22]\] and greater than that reported from Nigeria \[[@CR39]\]. Such variations in TSR could be attributed to differences in socio-economic of the patients, geographic setting, sample size, study period and the TB clinic management.

In the present study, 32.2% of PTB+ cases among who adhere and complete their treatment did not provide sputum for AFB examination according to the guideline \[[@CR33]\] or their smear results were not recorded. This could be due to lack of commitment of health professionals and/or poor awareness of PTB+ patients for checking their status during treatment.

During the study period, there was an increment of TSR for the first 5 years and then decline between July 2012 and June 2013. The decline of TSR could be due to lack of continues support/encouragement for people working in TB clinic and/or poor awareness of TB patients.

Male and TB/HIV co-infected cases demonstrated lower treatment success and this was in agreement with the findings reported in Ethiopia \[[@CR10], [@CR16], [@CR19], [@CR22]\] and in Malawi \[[@CR46]\]. Low treatment success in males could be attributed to risk-taking behavior like use of tobacco, alcohol and illicit drug \[[@CR47]\] and in TB/HIV co-infected patients could be due to co-administration of ART along with anti-TB therapy which can lead to drug--drug interactions, overlapping drug toxicities and immune reconstitution syndrome \[[@CR48]\].

In agreement with the studies in Ethiopia \[[@CR22]\] and in Malawi \[[@CR49]\], PTB+ cases in this study was associated with a higher treatment success which could be due to the easier accessibility of the drugs to the TB bacilli as the granuloma is usually burst in PTB+ cases and could also be due to more number of TB/HIV co-infected cases and higher number of death in PTB− patients. In addition, transfer-in patients had high probability of treatment success. It could be due to patients desire to be in an ideal health facility to continue and complete their treatment.

The percentage of overall unsuccessful treatment outcomes reported by the present study was similar with some studies \[[@CR12], [@CR17], [@CR22]\] while greater than other studies \[[@CR8]--[@CR11], [@CR13]--[@CR16], [@CR18], [@CR20], [@CR21], [@CR23], [@CR24]\]. Greater numbers of unsuccessful TB cases in the present study could be attributed to being in a remote area which leads to poor knowledge and having poor socio-economic status together reduces treatment adherence \[[@CR27], [@CR28]\].

Conclusion and recommendations {#Sec13}
------------------------------

The TSR recorded in the present study was less than the target to be met by 2015. This implies the necessity of urgent management response to improve current TSR. The low percentage of cure rate in PTB+ patients could suggest the strengthening of services of TB Clinic of the JGH. This is an area that needs health system level intervention. HIV positivity and male gender were associated with poor treatment success which requires targeted TB control management. Hence, improvement and strengthening of comprehensive and targeted TB--HIV control program are recommended to the study area.

Limitations {#Sec14}
===========

This study had the following limitations and born from being secondary data: lack of HIV status for the significant number of cases that could affect treatment outcomes, the low percentage of PTB+ cases which could be attributed to negligence or poor skills of the technicians, inadequate sputum examination records for PTB+ cases during treatment which could be due to the negligence of health professionals and could be a reason for low cure rate and for only one treatment failure case, and finally a high percentage of transfer out cases which could be attributed to the long distance between the Hospital and living districts of the patients which obliges the transfer out of the patients so that they can be treated at the nearby health center.

Additional file {#Sec15}
===============

**Additional file 1.** 10 years (2004--2014) TB DOTS data of JGH, Ethiopia. This is a file which contains information has been used for data analysis.
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